CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. MARKET SHARE ANALYSIS, 2016
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increase in focus of key players to develop combination therapies for the treatment of ophthalmic disorders
3.5.1.2. Rise in prevalence of ophthalmic disorders worldwide
3.5.1.3. Change in the demographics across the globe

3.5.2. Restraints

3.5.2.1. Longer timelines required for the development of ophthalmic drugs
3.5.2.2. Risk of side effects associated with ophthalmic drugs

3.5.3. Opportunity

3.5.3.1. Increase in investment by market players in the emerging economies

CHAPTER 4 OPHTHALMIC DRUGS MARKET, BY INDICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. DRY EYE

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. GLAUCOMA

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. INFECTION/INFLAMMATION/ALLERGY

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. RETINAL DISORDERS

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.5.4. Wet age-related macular degeneration

4.5.4.1. Market size and forecast

4.5.5. Dry age-related macular degeneration

4.5.5.1. Market size and forecast

4.5.6. Diabetic retinopathy

4.5.6.1. Market size and forecast

4.5.7. Others

4.5.7.1. Market size and forecast

4.6. OTHERS

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

CHAPTER 5 OPHTHALMIC DRUGS MARKET, BY TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. PRESCRIPTION DRUGS

5.2.1. Market size and forecast

5.3. OVER-THE-COUNTER DRUGS

5.3.1. Market size and forecast

CHAPTER 6 OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. HOSPITAL PHARMACIES

6.2.1. Market size and forecast

6.3. DRUG STORES

6.3.1. Market size and forecast

6.4. ONLINE PHARMACIES

6.4.1. Market size and forecast

6.5. OTHERS

6.5.1. Market size and forecast

CHAPTER 7 OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. LIQUID OPHTHALMIC DRUG FORMS

7.2.1. Market size and forecast

7.3. SEMISOLID OPHTHALMIC DRUG FORMS

7.3.1. Market size and forecast

7.4. SOLID OPHTHALMIC DRUG FORMS

7.4.1. Market size and forecast

7.5. MULTICOMPARTMENT DRUG DELIVERY SYSTEMS

7.5.1. Market size and forecast

7.6. OTHER OPHTHALMIC DRUG FORMS

7.6.1. Market size and forecast

CHAPTER 8 OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. ANTI-INFLAMMATORY

8.2.1. Market size and forecast
8.2.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)
8.2.3. Steroids

8.3. ANTI-INFECTIVE

8.3.1. Market size and forecast
8.3.2. Antifungal drugs
8.3.3. Antibacterial drugs
8.3.4. Others

8.4. ANTI-GLAUCOMA

8.4.1. Market size and forecast
8.4.2. Beta blockers
8.4.3. Prostaglandin analogs
8.4.4. Others

8.5. ANTI-ALLERGY

8.5.1. Market size and forecast

CHAPTER 9 OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY

9.1. OVERVIEW

9.1.1. Market size and forecast

9.2. BIOLOGICS

9.2.1. Market size and forecast

9.3. CELL THERAPY

9.3.1. Market size and forecast

9.4. GENE THERAPY

9.4.1. Market size and forecast

9.5. SMALL MOLECULE

9.5.1. Market size and forecast

9.6. DRUG DELIVERY

9.6.1. Market size and forecast

9.7. OTHERS

9.7.1. Market size and forecast

CHAPTER 10 OPHTHALMIC DRUGS MARKET, BY REGION

10.1. OVERVIEW

10.1.1. Market size and forecast

10.2. NORTH AMERICA

10.2.1. Key market trends
10.2.2. Key growth factors and opportunities
10.2.3. Market size and forecast, by country
10.2.4. Market size and forecast, by indication
10.2.5. Market size and forecast, by type
10.2.6. Market size and forecast, by technology
10.2.7. Market size and forecast, by distribution channel
10.2.8. Market size and forecast, by dosage form
10.2.9. Market size and forecast, by therapeutic class

10.2.9.1. U.S., by indication
10.2.9.2. U.S., by type
10.2.9.3. U.S., by distribution channel
10.2.9.4. U.S., by dosage form
10.2.9.5. U.S., by technology
10.2.9.6. U.S., by therapeutic class
10.2.9.7. Canada, by indication
10.2.9.8. Canada, by type
10.2.9.9. Canada, by distribution channel
10.2.9.10. Canada, by dosage form
10.2.9.11. Canada, by technology
10.2.9.12. Canada, by therapeutic class
10.2.9.13. Mexico, by indication
10.2.9.14. Mexico, by type
10.2.9.15. Mexico, by distribution channel
10.2.9.16. Mexico, by dosage form
10.2.9.17. Mexico, by technology
10.2.9.18. Mexico, by therapeutic class

10.3. EUROPE

10.3.1. Key market trends
10.3.2. Key growth factors and opportunities
10.3.3. Europe Market size and forecast, by country
10.3.4. Market size and forecast, by indication
10.3.5. Market size and forecast, by type
10.3.6. Market size and forecast, by technology
10.3.7. Market size and forecast, by distribution channel
10.3.8. Market size and forecast, by dosage form
10.3.9. Market size and forecast, by therapeutic class

10.3.9.1. Germany, by indication
10.3.9.2. Germany, by type
10.3.9.3. Germany, by distribution channel
10.3.9.4. Germany, by dosage form
10.3.9.5. Germany, by technology
10.3.9.6. Germany, by therapeutic class
10.3.9.7. France, by indication
10.3.9.8. France, by type
10.3.9.9. France, by distribution channel
10.3.9.10. France, by dosage form
10.3.9.11. France, by technology
10.3.9.12. France, by therapeutic class
10.3.9.13. UK, by indication
10.3.9.14. UK, by type
10.3.9.15. UK, by distribution channel
10.3.9.16. UK, by dosage form
10.3.9.17. UK, by technology
10.3.9.18. UK, by therapeutic class
10.3.9.19. Italy, by indication
10.3.9.20. Italy, by type
10.3.9.21. Italy, by distribution channel
10.3.9.22. Italy, by dosage form
10.3.9.23. Italy, by technology
10.3.9.24. Italy, by therapeutic class
10.3.9.25. Spain, by indication
10.3.9.26. Spain, by type
10.3.9.27. Spain, by distribution channel
10.3.9.28. Spain, by dosage form
10.3.9.29. Spain, by technology
10.3.9.30. Spain, by therapeutic class
10.3.9.31. Rest of Europe, by indication
10.3.9.32. Rest of Europe, by type
10.3.9.33. Rest of Europe, by distribution channel
10.3.9.34. Rest of Europe, by dosage form
10.3.9.35. Rest of Europe, by technology
10.3.9.36. Rest of Europe, by therapeutic class

10.4. ASIA-PACIFIC

10.4.1. Key market trends
10.4.2. Key growth factors and opportunities
10.4.3. Asia-Pacific Market size and forecast, by country
10.4.4. Market size and forecast, by indication
10.4.5. Market size and forecast, by type
10.4.6. Market size and forecast, by technology
10.4.7. Market size and forecast, by distribution channel
10.4.8. Market size and forecast, by dosage form
10.4.9. Market size and forecast, by therapeutic class

10.4.9.1. Japan, by indication
10.4.9.2. Japan, by type
10.4.9.3. Japan, by distribution channel
10.4.9.4. Japan, by dosage form
10.4.9.5. Japan, by technology
10.4.9.6. Japan, by therapeutic class
10.4.9.7. China, by indication
10.4.9.8. China, by type
10.4.9.9. China, by distribution channel
10.4.9.10. China, by dosage form
10.4.9.11. China, by technology
10.4.9.12. China, by therapeutic class
10.4.9.13. India, by indication
10.4.9.14. India, by type
10.4.9.15. India, by distribution channel
10.4.9.16. India, by dosage form
10.4.9.17. India, by technology
10.4.9.18. India, by therapeutic class
10.4.9.19. Australia, by indication
10.4.9.20. Australia, by type
10.4.9.21. Australia, by distribution channel
10.4.9.22. Australia, by dosage form
10.4.9.23. Australia, by technology
10.4.9.24. Australia, by therapeutic class
10.4.9.25. South Korea, by indication
10.4.9.26. South Korea, by type
10.4.9.27. South Korea, by distribution channel
10.4.9.28. South Korea, by dosage form
10.4.9.29. South Korea, by technology
10.4.9.30. South Korea, by therapeutic class
10.4.9.31. Rest of Asia-Pacific, by indication
10.4.9.32. Rest of Asia-Pacific, by type
10.4.9.33. Rest of Asia-Pacific, by distribution channel
10.4.9.34. Rest of Asia-Pacific, by dosage form
10.4.9.35. Rest of Asia-Pacific, by technology
10.4.9.36. Rest of Asia-Pacific, by therapeutic class

10.5. LAMEA

10.5.1. Key market trends
10.5.2. Key growth factors and opportunities
10.5.3. LAMEA Market size and forecast, by country
10.5.4. Market size and forecast, by indication
10.5.5. Market size and forecast, by type
10.5.6. Market size and forecast, by technology
10.5.7. Market size and forecast, by distribution channel
10.5.8. Market size and forecast, by dosage form
10.5.9. Market size and forecast, by therapeutic class

10.5.9.1. Brazil, by indication
10.5.9.2. Brazil, by type
10.5.9.3. Brazil, by distribution channel
10.5.9.4. Brazil, by dosage form
10.5.9.5. Brazil, by technology
10.5.9.6. Brazil, by therapeutic class
10.5.9.7. South Africa, by indication
10.5.9.8. South Africa, by type
10.5.9.9. South Africa, by distribution channel
10.5.9.10. South Africa, by dosage form
10.5.9.11. South Africa, by technology
10.5.9.12. South Africa, by therapeutic class
10.5.9.13. Turkey, by indication
10.5.9.14. Turkey, by type
10.5.9.15. Turkey, by distribution channel
10.5.9.16. Turkey, by dosage form
10.5.9.17. Turkey, by technology
10.5.9.18. Turkey, by therapeutic class
10.5.9.19. Saudi Arabia, by indication
10.5.9.20. Saudi Arabia, by type
10.5.9.21. Saudi Arabia, by distribution channel
10.5.9.22. Saudi Arabia, by dosage form
10.5.9.23. Saudi Arabia, by technology
10.5.9.24. Saudi Arabia, by therapeutic class
10.5.9.25. Rest of LAMEA, by indication
10.5.9.26. Rest of LAMEA, by type
10.5.9.27. Rest of LAMEA, by distribution channel
10.5.9.28. Rest of LAMEA, by dosage form
10.5.9.29. Rest of LAMEA, by technology
10.5.9.30. Rest of LAMEA, by therapeutic class

CHAPTER 11 COMPANY PROFILES

11.1. ALLERGAN PLC

11.1.1. Company overview
11.1.2. Company snapshot
11.1.3. Operating business segments
11.1.4. Product portfolio
11.1.5. Business performance
11.1.6. Key strategic moves and developments

11.2. F. HOFFMANN-LA ROCHE AG (GENENTECH, INC.)

11.2.1. Company overview
11.2.2. Company snapshot
11.2.3. Operating business segments
11.2.4. Product portfolio
11.2.5. Business performance
11.2.6. Key strategic moves and developments

11.3. NOVARTIS AG (ALCON-A DIVISION OF NOVARTIS)

11.3.1. Company overview
11.3.2. Company snapshot
11.3.3. Operating business segments
11.3.4. Product portfolio
11.3.5. Business performance
11.3.6. Key strategic moves and developments

11.4. PFIZER INC.

11.4.1. Company overview
11.4.2. Company snapshot
11.4.3. Operating business segments
11.4.4. Product portfolio
11.4.5. Business performance
11.4.6. Key strategic moves and developments

11.5. REGENERON PHARMACEUTICALS INC.

11.5.1. Company overview
11.5.2. Company snapshot
11.5.3. Operating business segments
11.5.4. Product portfolio
11.5.5. Business performance
11.5.6. Key strategic moves and developments

11.6. SANTEN PHARMACEUTICAL CO., LTD.

11.6.1. Company overview
11.6.2. Company snapshot
11.6.3. Operating business segments
11.6.4. Product portfolio
11.6.5. Business performance
11.6.6. Key strategic moves and developments

11.7. SHIRE PLC

11.7.1. Company overview
11.7.2. Company snapshot
11.7.3. Operating business segments
11.7.4. Product portfolio
11.7.5. Business performance
11.7.6. Key strategic moves and developments

11.8. SUN PHARMACEUTICAL INDUSTRIES LIMITED

11.8.1. Company overview
11.8.2. Company snapshot
11.8.3. Operating business segments
11.8.4. Product portfolio
11.8.5. Business performance
11.8.6. Key strategic moves and developments

11.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.( ACTAVIS GENERICS)

11.9.1. Company overview
11.9.2. Company snapshot
11.9.3. Operating business segments
11.9.4. Product portfolio
11.9.5. Business performance
11.9.6. Key strategic moves and developments

11.10. VALEANT PHARMACEUTICAL INTERNATIONAL, INC. (BAUSCH & LOMB INC.)

11.10.1. Company overview
11.10.2. Company snapshot
11.10.3. Operating business segments
11.10.4. Product portfolio
11.10.5. Business performance
11.10.6. Key strategic moves and developments